<DOC>
	<DOCNO>NCT00248170</DOCNO>
	<brief_summary>Eligible patient post-menopausal hormone receptor- lymph node-positive female recently underwent primary surgery breast cancer . Patients randomized letrozole ( 2.5 mg per day 5 year ) vs anastrozole ( 1 mg per day 5 year ) . Follow occur 5 year completion enrollment survival disease status update .</brief_summary>
	<brief_title>Comparison Trial Letrozole Anastrozole Adjuvant Treatment Postmenopausal Women With Hormone Receptor Node Positive Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Anastrozole</mesh_term>
	<mesh_term>Letrozole</mesh_term>
	<criteria>Recent primary surgery breast cancer Early stage breast cancer Postmenopausal Hormone receptor positive Positive lymph node involvement Metastatic disease Presence contralateral breast cancer include DCIS Progression Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>Female</gender>
	<minimum_age>33 Years</minimum_age>
	<maximum_age>96 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Breast cancer</keyword>
	<keyword>letrozole</keyword>
	<keyword>anastrozole</keyword>
	<keyword>adjuvant</keyword>
	<keyword>postmenopausal</keyword>
	<keyword>FACE</keyword>
</DOC>